Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...

Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...

The at-home test kits are designed to detect current COVID-19 variants, and can be used through the end of this year.

The mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Currently, the KP.3 and KP.3.1.1 FLiRT variants, derivatives of KP.1 and KP.2, are the most prevalent in Canada and the ...

Updated rapid tests are expected to be able to detect newer variants just as a new COVID variant arrives in Michigan.

Pfizer stock (NYSE: PFE) is trading at about $30 per share, not far from the lows seen in recent years. Could the stock rise by over 2x in value over the next few years? Does this sound a bit ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...

The pill had already received a mixed reception from physicians. A legal battle between Pfizer and Moderna over their rival ...

Comirnaty targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the XBB.1.5 subvariant ...